Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Year in review

- PMLiVE

Harnessing the power of omnichannel for impactful HCP engagement

Are you making best use of available channels to deliver meaningful engagement with HCPs? This article offers insight on the key building blocks for an effective omnichannel approach.

EPG Health

- PMLiVE

WHO announces launch of new pandemic preparedness initiative

The guidance focuses on respiratory pathogens, including influenza and RSV

- PMLiVE

WHO and global partners launch new effort to address falling childhood vaccination rates

Over 25 million children missed at least one vaccination in 2021 alone

- PMLiVE

NHS spring COVID-19 booster programme opens up for those at highest risk

Around five million people are eligible for the booster in line with the JCVI’s advice

- PMLiVE

Authorisation for Moderna and Pfizer/BioNTech’s bivalent COVID-19 vaccines simplified by FDA

The vaccines are now authorised for all doses in individuals aged six months and older

- PMLiVE

Gilead’s COVID-19 treatment shows promising results in vulnerable patient populations

Veklury demonstrated a reduction in mortality and hospital readmission rates

Mednet Mental Health Strategy 2023

We've launched our mental health strategy for the year to support our colleagues in maintaining positive mental health.

Mednet Group

The speed of science and the pace of comms

Pharma red tape slows comms but there is a solution, Paul Hutchings, founder of fox&cat, writes.

Fox&Cat

- PMLiVE

BioNTech reveals plans to spend about €1bn more on research and development this year

The company has already started clinical trials assessing four new infectious disease vaccines

- PMLiVE

WHO report highlights impact of COVID-19 pandemic on non-communicable diseases

These diseases were responsible for an estimated 40 million of all deaths globally in 2019

- PMLiVE

Pfizer/BioNTech’s Omicron-adapted booster approved by FDA for young children

The companies have also submitted an application to the EMA for this age group

- PMLiVE

JCVI recommends spring COVID-19 booster for those at highest risk

Eligible individuals will be offered the booster around six months after their previous dose

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links